Arbutus Biopharma Corporation
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- R9VYBEQJ57R8
-
- SAM.gov registration date
- Website
- arbutusbio.com
- Founded
- 2007
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Advanced development of hemorrhagic | ACC Aberdeen Proving Ground | $52,187,135 | |
| Tissue factor 500MG | Medical Command (Army) | $48,238 | |
| Custom sirna duplex | Medical Command (Army) | $52,700 | |
| Sirna duplex | Medical Command (Army) | $52,900 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Autonomous Therapeutics Inc. | Silver Spring, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Harlingene Life Sciences LLC | Doylestown, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Hbvtech, L.l.c | Germantown, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Advac Therapeutic LLC | Philadelphia, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Akanocure Pharmaceuticals Inc. | West Lafayette, IN | — |
About the company
Arbutus Biopharma Corporation is a for-profit organization registered to receive federal government awards since November 6, 2008. The company operates as a parent entity and has been involved in both federal contract and grant sub-award activities. Arbutus Biopharma Corporation specializes in developing novel drugs for treating chronic hepatitis B virus (HBV) infection, leveraging its expertise in RNA interference and lipid nanoparticle drug delivery. While the company has a history of federal contract awards, its most recent federal contract award dates back to July 14, 2010.
In recent years, Arbutus Biopharma Corporation's involvement in federal funding has primarily been through its subsidiary, Genevant Sciences Corp. Genevant Sciences Corp has received multiple federal grant sub-awards from the University of Texas Medical Branch at Galveston, focusing on the development of RNA interference therapeutics for viral infections. These sub-awards, funded by the Department of Health and Human Services, aim to identify and develop a broad-spectrum siRNA-based therapeutic for post-exposure treatment and prophylaxis of Ebolavirus and Marburg virus (MARV) infections. The specific objectives include identifying lead candidates, demonstrating pre-clinical activity, and establishing efficacy proof-of-concept for a N-acetylgalactosamine (GalNAc) conjugated siRNA therapeutic. This therapeutic is intended to provide primary and secondary prophylaxis against various Ebolavirus species and MARV, addressing a critical need in combating these highly pathogenic filovirus infections.
Quick answers
Is Arbutus Biopharma Corporation registered in SAM.gov?
Arbutus Biopharma Corporation's SAM.gov registration expired on March 11, 2020.
What is Arbutus Biopharma Corporation's CAGE code?
Arbutus Biopharma Corporation's CAGE code is L8144, and its Unique Entity ID (UEI) is Z6GEANC7LJP1.
What is Arbutus Biopharma Corporation's most recent federal award?
Arbutus Biopharma Corporation's most recent federal contract award is Advanced development of hemorrhagic (W9113M10C0057), from ACC Aberdeen Proving Ground, on July 14, 2010.
On GovTribe
See Arbutus Biopharma Corporation's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors